LONNEL COATS
CIK 1612528 · Chief Executive Officer · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.78M
Companies
4
Total Filings
55
Lifetime Open-Market Net
-$1.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLAY | Director | — | $19.94 | — | $0 | 2 | 2026-06-10 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 5 | 2025-07-28 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$2.69M | 15 | 2025-07-21 |
| LXRX | Chief Executive Officer | 1,159,439 | $2.40 | $2.78M | $1.11M | 30 | 2024-02-29 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-28 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,242 | $0 | EDGAR |
| 2024-02-29 | LXRX | Mixed | +183,709 | -$160.8K | EDGAR |
| 2024-02-12 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | LXRX | Buy (P) | +90,000 | $94.8K | EDGAR |
| 2023-11-13 | LXRX | Buy (P) | +10,000 | $10.1K | EDGAR |
| 2023-06-29 | LXRX | Buy (P) | +10,000 | $21.6K | EDGAR |
| 2023-06-26 | LXRX | Buy (P) | +20,000 | $46.7K | EDGAR |
| 2023-06-23 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,600 | $0 | EDGAR |
| 2023-06-22 | LXRX | Buy (P) | +40,000 | $92.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.